Centre empowers State Drug Authorities to debar pharma firms for fake data

The Centre has amended the Drugs Rules, 1945, empowering State Drug Control Authorities to debar pharmaceutical companies that submit fake or misleading data while seeking approvals. The revised rules also mandate due process, including show-cause notices and a 30-day appeal mechanism.

Hyderabad: In a move aimed at imposing stricter punishment on pharma companies that furnish wrong information while seeking permissions, State Drug Control Authorities (DCAs) can now completely lock out and debar institutions caught submitting fake, fabricated, or misleading data from filing any future approvals for a specified duration.

In major amendments to the Drugs Rules, 1945, through a notification issued on Thursday by the Union Ministry of Health and Family Welfare, the state DCAs are no longer restricted to just rejecting applications or license cancellations.

---

Till now, if pharma companies submitted falsified data while seeking permissions, the DCAs had powers only to impose penalties or withdraw active permits.

The new provisions, however, now grant the state DCAs and even the central regulators explicit statutory powers to block fraudulent entities from re-engaging with the regulatory system altogether across all application categories.

The MOHFW and regulators pointed out that proper scientific data forms the basis of ensuring quality of drugs, their safety, and public health. The new stricter rules will ensure falsified evidence is not submitted, which goes a long way in strengthening oversight and prevents introduction of vulnerabilities into domestic and international pharmaceutical supply chains.

According to MOHFW, the stricter norms and enhanced interventions are aligned with international best practices to zero in on repeat offenders and also encourage fair competition among globally compliant pharma manufacturers.

To ensure these expanded powers for State DCAs are implemented fairly, the updated framework also strives to implement strict administrative checks and balances. To this effect, state DCAs must issue a mandatory written show-cause notice to the pharma companies detailing the specific grounds for punitive action before any debarment takes place.

Pharma companies can employ/retain legal recourse, allowing them to file a formal appeal within 30 days for a structured review and hearing. By pairing severe deterrent lockouts with transparent due process, the Centre aims to weed out unscrupulous operators and elevate compliant manufacturers.

What are the new rules?

State Drug Control Authorities (DCAs) are now empowered

DCAs can debar pharma companies that submit fake, fabricated, or misleading data

Penalty extends beyond simple application rejections or license cancellations

DCAs can blacklist pharma companies from filing future regulatory approvals

New provisions apply universally across all application categories under Drugs Rules, 1945

Regulators have to issue a formal, written show-cause notice detailing grounds for punitive action before any debarment order takes effect

Aggrieved applicants can appeal within 30 days, complete with inquiry protocols and a right to a hearing